• XSTEM license deal possible in 2024
• Targinta develops tumour-directed cancer treatments in a hot field
• We initiate coverage with a fair value of SEK 1.30 per share

Xintela is a biopharma company with two assets in clinical development phase. The company focuses on stem cell therapy and cancer therapy based on the cell surface receptor integrin α10β1. Our view is that Xintela’s current market cap of SEK 140 million does not reflect the potential of its pipeline. In Xintela, we find a broad promising pipeline, a strong IP situation, a supportive main shareholder and high interest from the industry for the indication areas.

The full report is available here.